Literature DB >> 28468845

BDNF Val66Met predicts cognitive decline in the Wisconsin Registry for Alzheimer's Prevention.

Elizabeth A Boots1, Stephanie A Schultz1, Lindsay R Clark1, Annie M Racine1, Burcu F Darst1, Rebecca L Koscik1, Cynthia M Carlsson1, Catherine L Gallagher1, Kirk J Hogan1, Barbara B Bendlin1, Sanjay Asthana1, Mark A Sager1, Bruce P Hermann1, Bradley T Christian1, Dena B Dubal1, Corinne D Engelman1, Sterling C Johnson1, Ozioma C Okonkwo2.   

Abstract

OBJECTIVE: To examine the influence of the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism on longitudinal cognitive trajectories in a large, cognitively healthy cohort enriched for Alzheimer disease (AD) risk and to understand whether β-amyloid (Aβ) burden plays a moderating role in this relationship.
METHODS: One thousand twenty-three adults (baseline age 54.94 ± 6.41 years) enrolled in the Wisconsin Registry for Alzheimer's Prevention underwent BDNF genotyping and cognitive assessment at up to 5 time points (average follow-up 6.92 ± 3.22 years). A subset (n = 140) underwent 11C-Pittsburgh compound B (PiB) scanning. Covariate-adjusted mixed-effects regression models were used to elucidate the effect of BDNF on cognitive trajectories in 4 cognitive domains, including verbal learning and memory, speed and flexibility, working memory, and immediate memory. Secondary mixed-effects regression models were conducted to examine whether Aβ burden, indexed by composite PiB load, modified any observed BDNF-related cognitive trajectories.
RESULTS: Compared to BDNF Val/Val homozygotes, Met carriers showed steeper decline in verbal learning and memory (p = 0.002) and speed and flexibility (p = 0.017). In addition, Aβ burden moderated the relationship between BDNF and verbal learning and memory such that Met carriers with greater Aβ burden showed even steeper cognitive decline (p = 0.033).
CONCLUSIONS: In a middle-aged cohort with AD risk, carriage of the BDNF Met allele was associated with steeper decline in episodic memory and executive function. This decline was exacerbated by greater Aβ burden. These results suggest that the BDNF Val66Met polymorphism may play an important role in cognitive decline and could be considered as a target for novel AD therapeutics.
© 2017 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28468845      PMCID: PMC5447398          DOI: 10.1212/WNL.0000000000003980

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  39 in total

1.  Improved kinetic analysis of dynamic PET data with optimized HYPR-LR.

Authors:  John M Floberg; Charles A Mistretta; Jamey P Weichert; Lance T Hall; James E Holden; Bradley T Christian
Journal:  Med Phys       Date:  2012-06       Impact factor: 4.071

2.  BDNF val66met polymorphism affects aging of multiple types of memory.

Authors:  Kristen M Kennedy; Elizabeth D Reese; Marci M Horn; April N Sizemore; Asha K Unni; Michael E Meerbrey; Allan G Kalich; Karen M Rodrigue
Journal:  Brain Res       Date:  2014-09-28       Impact factor: 3.252

3.  Physical activity attenuates age-related biomarker alterations in preclinical AD.

Authors:  Ozioma C Okonkwo; Stephanie A Schultz; Jennifer M Oh; Jordan Larson; Dorothy Edwards; Dane Cook; Rebecca Koscik; Catherine L Gallagher; N M Dowling; Cynthia M Carlsson; Barbara B Bendlin; Asenath LaRue; Howard A Rowley; Brad T Christian; Sanjay Asthana; Bruce P Hermann; Sterling C Johnson; Mark A Sager
Journal:  Neurology       Date:  2014-10-08       Impact factor: 9.910

4.  Association between BDNF polymorphism (Val66Met) and executive function in patients with amnestic mild cognitive impairment or mild Alzheimer disease.

Authors:  Tomoyuki Nagata; Shunichiro Shinagawa; Kazutaka Nukariya; Hisashi Yamada; Kazuhiko Nakayama
Journal:  Dement Geriatr Cogn Disord       Date:  2012-06-13       Impact factor: 2.959

Review 5.  Brain-derived neurotrophic factor and Alzheimer's disease: physiopathology and beyond.

Authors:  Breno Satler Diniz; Antonio Lucio Teixeira
Journal:  Neuromolecular Med       Date:  2011-09-07       Impact factor: 3.843

Review 6.  Cognitive reserve in ageing and Alzheimer's disease.

Authors:  Yaakov Stern
Journal:  Lancet Neurol       Date:  2012-11       Impact factor: 44.182

7.  The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function.

Authors:  Michael F Egan; Masami Kojima; Joseph H Callicott; Terry E Goldberg; Bhaskar S Kolachana; Alessandro Bertolino; Eugene Zaitsev; Bert Gold; David Goldman; Michael Dean; Bai Lu; Daniel R Weinberger
Journal:  Cell       Date:  2003-01-24       Impact factor: 41.582

8.  Brain-derived neurotrophic factor polymorphism Val66Met influences cognitive abilities in the elderly.

Authors:  F Miyajima; W Ollier; A Mayes; A Jackson; N Thacker; P Rabbitt; N Pendleton; M Horan; A Payton
Journal:  Genes Brain Behav       Date:  2007-10-31       Impact factor: 3.449

9.  Serum brain-derived neurotrophic factor and the risk for dementia: the Framingham Heart Study.

Authors:  Galit Weinstein; Alexa S Beiser; Seung Hoan Choi; Sarah R Preis; Tai C Chen; Demetrios Vorgas; Rhoda Au; Aleksandra Pikula; Philip A Wolf; Anita L DeStefano; Ramachandran S Vasan; Sudha Seshadri
Journal:  JAMA Neurol       Date:  2014-01       Impact factor: 18.302

10.  Brain-derived neurotrophic factor ameliorates learning deficits in a rat model of Alzheimer's disease induced by aβ1-42.

Authors:  Lu Zhang; Yu Fang; Yajun Lian; Yuan Chen; Tianwen Wu; Yake Zheng; Huili Zong; Limin Sun; Ruifang Zhang; Zhenhua Wang; Yuming Xu
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

View more
  22 in total

1.  Sex-dependent effect of the BDNF Val66Met polymorphism on executive functioning and processing speed in older adults: evidence from the health ABC study.

Authors:  Cindy K Barha; Teresa Liu-Ambrose; John R Best; Kristine Yaffe; Caterina Rosano
Journal:  Neurobiol Aging       Date:  2018-10-23       Impact factor: 4.673

Review 2.  Born to Protect: Leveraging BDNF Against Cognitive Deficit in Alzheimer's Disease.

Authors:  Lucia Caffino; Francesca Mottarlini; Fabio Fumagalli
Journal:  CNS Drugs       Date:  2020-03       Impact factor: 5.749

Review 3.  Vascular and non-vascular contributors to memory reduction during traumatic brain injury.

Authors:  Mariam Charkviani; Nino Muradashvili; David Lominadze
Journal:  Eur J Neurosci       Date:  2019-03-12       Impact factor: 3.386

Review 4.  Regulation of DAPK1 by Natural Products: An Important Target in Treatment of Stroke.

Authors:  Tayebeh Noori; Samira Shirooie; Antoni Sureda; Eduardo Sobarzo-Sanchez; Ahmad Reza Dehpour; Marianela Saldías; Esra Küpeli Akkol
Journal:  Neurochem Res       Date:  2022-06-08       Impact factor: 4.414

5.  Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease.

Authors:  Yen Ying Lim; Jason Hassenstab; Alison Goate; Anne M Fagan; Tammie L S Benzinger; Carlos Cruchaga; Eric McDade; Jasmeer Chhatwal; Johannes Levin; Martin R Farlow; Neill R Graff-Radford; Christoph Laske; Colin L Masters; Stephen Salloway; Peter Schofield; John C Morris; Paul Maruff; Randall J Bateman
Journal:  Ann Neurol       Date:  2018-08-25       Impact factor: 10.422

6.  The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer's disease.

Authors:  Nicolai Franzmeier; Jinyi Ren; Alexander Damm; Gemma Monté-Rubio; Mercè Boada; Agustín Ruiz; Alfredo Ramirez; Frank Jessen; Emrah Düzel; Octavio Rodríguez Gómez; Tammie Benzinger; Alison Goate; Celeste M Karch; Anne M Fagan; Eric McDade; Katharina Buerger; Johannes Levin; Marco Duering; Martin Dichgans; Marc Suárez-Calvet; Christian Haass; Brian A Gordon; Yen Ying Lim; Colin L Masters; Daniel Janowitz; Cihan Catak; Steffen Wolfsgruber; Michael Wagner; Esther Milz; Sonia Moreno-Grau; Stefan Teipel; Michel J Grothe; Ingo Kilimann; Martin Rossor; Nick Fox; Christoph Laske; Jasmeer Chhatwal; Peter Falkai; Robert Perneczky; Jae-Hong Lee; Annika Spottke; Henning Boecker; Frederic Brosseron; Klaus Fliessbach; Michael T Heneka; Peter Nestor; Oliver Peters; Manuel Fuentes; Felix Menne; Josef Priller; Eike J Spruth; Christiana Franke; Anja Schneider; Christine Westerteicher; Oliver Speck; Jens Wiltfang; Claudia Bartels; Miguel Ángel Araque Caballero; Coraline Metzger; Daniel Bittner; Stephen Salloway; Adrian Danek; Jason Hassenstab; Igor Yakushev; Peter R Schofield; John C Morris; Randall J Bateman; Michael Ewers
Journal:  Mol Psychiatry       Date:  2019-03-21       Impact factor: 15.992

7.  Translational genomic research: the role of genetic polymorphisms in MBSR program among breast cancer survivors (MBSR[BC]).

Authors:  Jong Y Park; Cecile A Lengacher; Richard R Reich; Carissa B Alinat; Sophia Ramesar; Alice Le; Carly L Paterson; Michelle L Pleasant; Hyun Y Park; John Kiluk; Hyo Han; Roohi Ismail-Khan; Kevin E Kip
Journal:  Transl Behav Med       Date:  2019-07-16       Impact factor: 3.626

Review 8.  Brain-Derived Neurotrophic Factor Signaling in the Pathophysiology of Alzheimer's Disease: Beneficial Effects of Flavonoids for Neuroprotection.

Authors:  Tadahiro Numakawa; Haruki Odaka
Journal:  Int J Mol Sci       Date:  2021-05-27       Impact factor: 5.923

9.  Zinc induced structural changes in the intrinsically disordered BDNF Met prodomain confer synaptic elimination.

Authors:  Jing Wang; Agustin Anastasia; Henrietta Bains; Joanna I Giza; David G Clossey; Jingjing Deng; Thomas A Neubert; William J Rice; Francis S Lee; Barbara L Hempstead; Clay Bracken
Journal:  Metallomics       Date:  2020-08-19       Impact factor: 4.636

Review 10.  Loss of Neuroprotective Factors in Neurodegenerative Dementias: The End or the Starting Point?

Authors:  Luisa Benussi; Giuliano Binetti; Roberta Ghidoni
Journal:  Front Neurosci       Date:  2017-12-01       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.